Cullinan Therapeutics (NASDAQ:CGEM) outlined a milestone-heavy roadmap during a presentation at Leerink Partners’ Annual ...

A topical cream activated the skin's immune defenses and suppressed tumor growth in two preclinical models of cutaneous squamous cell carcinoma (cSCC), according to a study published in the Journal of ...

Detailed price information for Vera Therapeutics Inc Cl A (VERA-Q) from The Globe and Mail including charting and trades.

Precision Bb Targeting, Robust Efficacy, Transfusion Independence, Excellent Safety in Phase II PNH Study, and Subcutaneous Administration Key Highlights: Monotherapy and Clinical Outcomes The ...

The FDA approved Darzalex Faspro with Velcade, Revlimid and dexamethasone for newly diagnosed multiple myeloma ineligible for autologous stem cell transplant. The U.S. Food and Drug Administration ...

If approved, a subcutaneous formulation of anifrolumab would allow patients the ability to self-administer the medication outside of a hospital or clinic setting. The Food and Drug Administration (FDA ...

A Prescription Drug User Fee Act target date of May 24, 2026 has been set for the application. Lecanemab is a humanized immunoglobulin gamma 1 monoclonal antibody directed against aggregated soluble ...

A Prescription Drug User Fee Act target date of May 24, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License ...

Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. The ASTRO double-blind ...

2. It may reduce reliance on high-dose opioids/benzodiazepines and, in some cases, postpone the need for palliative sedation therapy This retrospective single-centre chart review from a New Zealand ...

The combination of the pericapsular nerve group (PENG) block and lateral femoral cutaneous nerve (LFCN) block has garnered increasing attention as a postoperative analgesic strategy following hip ...